Ductal Breast Carcinoma In Situ Clinical Trial
Official title:
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:
I. Determine whether lapatinib (lapatinib ditosylate) therapy at the dose of 1000 mg results
in a statistically significantly lower rate of proliferation in ductal carcinoma in situ
(DCIS) breast cancer cells as measured by Ki67 when compared to placebo.
II. Determine the toxicity profile and frequency of adverse events in women with DCIS breast
cancer taking lapatinib at 1000 mg as compared to women taking placebo.
SECONDARY OBJECTIVES:
I. Determine whether lapatinib treatment affects the incidence of DCIS seen at the time of
surgical excision.
II. Determine whether treatment with lapatinib will modulate breast tissue histology or the
expression of specific biomarkers in normal and DCIS breast cancer cells.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive lapatinib ditosylate orally (PO) once daily (QD) for 2-6 weeks until
the time of surgery.
ARM II: Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
After completion of study treatment, patients are followed for 4-5 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02314156 -
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
|
Phase 2 | |
Completed |
NCT01874184 -
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT01905046 -
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
|
Phase 3 | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT02587663 -
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
|
N/A | |
Active, not recruiting |
NCT04537312 -
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
|
N/A | |
Active, not recruiting |
NCT01245712 -
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02993159 -
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
|
Phase 2 | |
Completed |
NCT01753908 -
Broccoli Sprout Extract in Treating Patients With Breast Cancer
|
Early Phase 1 | |
Terminated |
NCT02023008 -
Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy
|
N/A | |
Completed |
NCT01849250 -
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
|
Phase 2 | |
Terminated |
NCT01754519 -
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
|
Phase 2 | |
Completed |
NCT01819233 -
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT03077841 -
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02352883 -
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
|
N/A | |
Recruiting |
NCT03909282 -
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
|
N/A | |
Completed |
NCT01723943 -
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
|
N/A | |
Completed |
NCT00637481 -
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
|
Phase 1 | |
Completed |
NCT01975363 -
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03391388 -
3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer
|
Phase 2 |